JAMA Cardiology’s Post

A revolutionary new perception on anticoagulation treatment in patients with ACS undergoing PCI with DES. New insights that will most probably impact the upcoming guidelines

Most viewed in the last 7 days from JAMA Cardiology: In patients with ACS undergoing percutaneous coronary intervention with drug-eluting stents, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE. https://ja.ma/4iNmbpD

Most viewed in the last 7 days from JAMA Cardiology: The beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent for patients who experienced percutaneous coronary intervention and were event-free during 6 to 18 months of dual antiplatelet therapy. https://ja.ma/49rxMqr

Most viewed in the last 7 days from JAMA Cardiology: The beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent for patients who experienced percutaneous coronary intervention and were event-free during 6 to 18 months of dual antiplatelet therapy. https://ja.ma/4gmoGgD

Most viewed in the last 7 days from JAMA Cardiology: What is the optimal duration of dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention with drug-eluting stents? https://ja.ma/3A3usEs

Most viewed in the last 7 days from JAMA Cardiology: What is the optimal duration of dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention with drug-eluting stents? https://ja.ma/4frqg0z

Most viewed in the last 7 days from JAMA Cardiology: Study examines the effects of cardiac myosin inhibition with mavacamten in patients with HFpEF with left ventricular ejection fraction of 60% or greater. https://ja.ma/3zOc0Qb

Most viewed in the last 7 days from JAMA Cardiology: This narrative review analyzes associations among heart failure, aortic stenosis, and aortic valve replacement. https://ja.ma/3A1GNt3

Dr. Ashok Kumar’s insights on Hypertension will give you a chance to understand this topic in depth and will surely benefit you in your overall health scenario. Watch out this session 👇

ApoB has been the standard for many years. However, it hasn't even scratched the surface in clinical workflows. I suspect it will be another decade before it will be the standard of care. The reasons for this is that many medical groups are still using pre-printed (paper) for ordering labs, EHR order sets haven't been updated, patients still rely on outdated HDL and TG data, and reimbursement packages don't mention apoB and Lp(a). Lipidology isn't the only field in healthcare affected by entrenchment. This is health literacy. Not a curse word, but a patient empowerment tool.